drugset / Trial / NCT00139906
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
Phase 2
Completed
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
Timeline
- Start
- 2005-08
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | 40 mg | — |